Icatibanto Hikma

Icatibant, the active ingredient in Icatibanto Hikma, is a bradykinin B2 receptor antagonist presented as a solution for subcutaneous injection for subcutaneous use. It is indicated for the treatment of acute hereditary angioedema attacks in patients with C1‑inhibitor deficiency, reducing swelling and improving airway safety.

GNH USA supplies Icatibanto Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company provides regulated sourcing, quality assurance and global logistics to meet clinical demand.

Icatibant is used to manage hereditary angioedema by blocking the bradykinin pathway that causes swelling. - Acute hereditary angioedema attacks (type I): rapid reduction of edema and pain. - Acute hereditary angioedema attacks (type II): relief of airway obstruction risk. - Hereditary angioedema with C1‑inhibitor deficiency: restores vascular stability during episodes.

Common side effects are generally mild and related to the injection site or systemic response.

Common Side Effects: - Injection site pain: discomfort at the site of subcutaneous administration. - Redness or erythema: localized skin irritation. - Swelling at injection site: transient edema. - Nausea: mild gastrointestinal upset. - Headache: transient cephalic discomfort. - Dizziness: brief sensation of light‑headedness.

Serious or Rare Side Effects: - Hypersensitivity reaction: rash, itching, or hives. - Anaphylaxis: severe, potentially life‑threatening allergic response. - Paradoxical angioedema: worsening swelling despite therapy. - Severe hypotension: marked drop in blood pressure. - Thrombocytopenia: reduced platelet count. - Acute respiratory distress: difficulty breathing unrelated to HAE.

Before using Icatibanto Hikma, consider the following safety measures. - Pregnancy: safety not established; avoid unless benefit outweighs risk. - Breastfeeding: unknown; evaluate potential infant exposure. - Renal impairment: use with caution and monitor renal function. - Concomitant ACE inhibitors: may increase bradykinin levels; observe for enhanced edema. - Known hypersensitivity: discontinue immediately if severe allergic reaction occurs. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Icatibanto Hikma may interact with other medications that influence bradykinin pathways or fluid balance.

Major Interactions (Avoid): - ACE inhibitors: increased bradykinin may exacerbate edema. - Angiotensin receptor blockers: similar risk of heightened bradykinin effects. - Other bradykinin B2 antagonists: additive pharmacologic activity.

Moderate Interactions (Monitor Closely): - Diuretics: may alter fluid status and affect edema control. - Antihistamines: could mask mild hypersensitivity signs. - NSAIDs: monitor for potential renal effects when combined with bradykinin blockade.